A simplified model to understand the targeted disease-modifying anti-inflammatory drugs.
| Autor: | Kragstrup TW; Institut for Biomedicin, Aarhus Universitet.; Led- og Bindevævssygdomme, Aarhus Universitetshospital.; Klinik for Gigt- og Bindevævssygdomme, Regionshospitalet Silkeborg., Ottosen KJ; Institut for Biomedicin, Aarhus Universitet., Uhrenholt L; Led- og Bindevævssygdomme, Aarhus Universitetshospital.; Reumatologisk Afdeling, Aalborg Universitetshospital., Dalgaard EB; Klinik for Gigt- og Bindevævssygdomme, Regionshospitalet Silkeborg. |
|---|---|
| Jazyk: | dánština |
| Zdroj: | Ugeskrift for laeger [Ugeskr Laeger] 2024 Aug 12; Vol. 186 (33). |
| DOI: | 10.61409/V12230795 |
| Abstrakt: | This review presents a simplified model to understand better how disease-modifying anti-inflammatory drugs (DMAIDs) work in immune-mediated inflammatory diseases (IMIDs) with a focus on rheumatology, dermatology, and gastroenterology. In this model, IMIDs are listed on a spectrum from autoinflammatory to autoimmune characterised by the involvement of either mostly the innate or the adaptive immune system. DMAIDs specifically target these immune components and have shown efficacy in distinct IMIDs. DMAID classes include TNF blockers, IL-1 blockers, IL-6 receptor blockers, IL-17 blockers, IL-23 blockers, and janus kinase inhibitors. (Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|